Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Liping Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0399-1228; OpenAlex author ID A5108742397. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Using Machine Learning Methods to Develop Diagnostic and Prognostic mRNA Signatures for Pancreatic Cancer in Plasma Small Extracellular Vesicles. Last author DOI 10.1007/s10620-025-08867-6↗
  2. Correction: Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Last author DOI 10.1038/s41419-023-06399-3↗
  3. Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2021.121176↗
  4. IFN-γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN-γ response. Last author DOI 10.3892/ol.2018.7777↗
  5. Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. Last author DOI 10.3233/cbm-160671↗
  6. Overexpressions of DLL4 and CD105 are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s12253-015-9937-4↗
  7. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Last author DOI 10.18632/oncotarget.4924↗
  8. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Last author DOI 10.1016/j.cellimm.2014.09.004↗
  9. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. Last author DOI 10.1186/1477-7819-11-219↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guoping Ding · 7 shared papers, 2013–2024 · strength 0.69
  2. Shengnan Jia · 2 shared papers, 2024–2025 · strength 0.68
  3. Zhen Liu · 1 shared paper, 2025 · strength 0.42
  4. Liangjing Zhou · 5 shared papers, 2014–2018 · strength 0.38
  5. Xiaodong Xu · 1 shared paper, 2024 · strength 0.26
  6. Jionghuang Chen · 3 shared papers, 2013–2015 · strength 0.15
  7. Tao Shen · 1 shared paper, 2018 · strength 0.12
  8. Xiangsheng Liu · 1 shared paper, 2021 · strength 0.12
  9. Quan Zhou · 1 shared paper, 2021 · strength 0.12
  10. Haiping Jiang · 1 shared paper, 2021 · strength 0.12
  11. Youqing Shen · 1 shared paper, 2021 · strength 0.12
  12. Xiangrui Liu · 1 shared paper, 2021 · strength 0.12
  13. Liying Wang · 1 shared paper, 2021 · strength 0.12
  14. Huan Meng · 1 shared paper, 2021 · strength 0.12
  15. Zhengrong Wu · 1 shared paper, 2017 · strength 0.10
  16. Risheng Que · 1 shared paper, 2013 · strength 0.05
  17. Min Zhou · 1 shared paper, 2014 · strength 0.05
  18. Guixing Jiang · 1 shared paper, 2015 · strength 0.05
  19. Zhengrong Wu · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.